Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
5.20
+0.07 (1.36%)
At close: Feb 6, 2026, 4:00 PM EST
5.17
-0.03 (-0.58%)
After-hours: Feb 6, 2026, 7:35 PM EST
Niagen Bioscience Revenue
Niagen Bioscience had revenue of $33.99M in the quarter ending September 30, 2025, with 32.86% growth. This brings the company's revenue in the last twelve months to $124.71M, up 36.04% year-over-year. In the year 2024, Niagen Bioscience had annual revenue of $99.60M with 19.18% growth.
Revenue (ttm)
$124.71M
Revenue Growth
+36.04%
P/S Ratio
3.27
Revenue / Employee
$1,199,125
Employees
104
Market Cap
416.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 99.60M | 16.03M | 19.18% |
| Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
| Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
| Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
| Dec 31, 2020 | 59.26M | 12.97M | 28.01% |
| Dec 31, 2019 | 46.29M | 14.73M | 46.69% |
| Dec 31, 2018 | 31.56M | 10.36M | 48.85% |
| Dec 30, 2017 | 21.20M | -463.65K | -2.14% |
| Dec 31, 2016 | 21.66M | 3.78M | 21.13% |
| Jan 2, 2016 | 17.88M | 2.57M | 16.79% |
| Jan 3, 2015 | 15.31M | 5.15M | 50.71% |
| Dec 28, 2013 | 10.16M | -1.45M | -12.48% |
| Dec 29, 2012 | 11.61M | 3.50M | 43.12% |
| Dec 31, 2011 | 8.11M | 546.24K | 7.22% |
| Jan 1, 2011 | 7.57M | 1.79M | 30.95% |
| Jan 2, 2010 | 5.78M | 1.27M | 28.22% |
| Jan 3, 2009 | 4.51M | -247.77K | -5.21% |
| Dec 29, 2007 | 4.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 212.07M |
| Assembly Biosciences | 37.19M |
| Lineage Cell Therapeutics | 10.82M |
| PureTech Health | 6.39M |
| 4D Molecular Therapeutics | 120.00K |
NAGE News
- 1 day ago - Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 - Business Wire
- 23 days ago - Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.* - Business Wire
- 6 weeks ago - Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast - Business Wire
- 3 months ago - Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years - Seeking Alpha
- 3 months ago - Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside) - Business Wire
- 3 months ago - Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID - Business Wire
- 3 months ago - Niagen Bioscience Announces $10 Million Share Repurchase Program - Business Wire
- 3 months ago - Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript - Seeking Alpha